FDA approves AbbVie next-gen dopamine therapy for Parkinson's
The FDA approved AbbVie’s next-generation therapy for Parkinson’s disease, tavapadon, a dopamine agonist that's expected to provide the symptom relief of its predecessors but with fewer side effects. Tavapadon will be branded as Juvmo and ...
The US Food and Drug Administration has approved AbbVie's treatment for Parkinson's disease in adults. The drug, tavapadon, will be sold under the brand name Juvmo and comes as a once-a-day pill. According to AbbVie, more than 11 million people live with Parkinson's disease worldwide.
Juvmo works by mimicking dopamine, a vital brain chemical that naturally decreases in people with Parkinson's. The FDA's approval was based on data from AbbVie's late-stage trial program, which showed the drug improved symptoms in patients with the disease. Common side effects reported in the trials included nausea, dizziness, and headache.
AbbVie gained access to tavapadon through its $8.7 billion acquisition of Cerevel Therapeutics in 2023. Citi analysts had previously said the launch was expected in the third quarter of 2026, with AbbVie targeting more than $5 billion in combined Parkinson's disease sales.
Brief written by urgent.news from Endpoints News, The Hindu - Sci-Tech, The Hindu Health — 3 reports on this story. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
